Anatolia Tani ve Biyoteknoloji Ürünleri Ar-Ge Sanayi Ticaret A.S. (ANGEN.IS)
- Previous Close
10.94 - Open
10.95 - Bid 10.87 x --
- Ask 10.87 x --
- Day's Range
10.79 - 10.95 - 52 Week Range
10.31 - 21.12 - Volume
1,656,843 - Avg. Volume
6,535,069 - Market Cap (intraday)
2.387B - Beta (5Y Monthly) -0.23
- PE Ratio (TTM)
-- - EPS (TTM)
-0.99 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date May 3, 2023
- 1y Target Est
--
Anatolia Tani ve Biyoteknoloji Ürünleri Ar-Ge Sanayi Ticaret A.S., a biotechnology company, engages in the design, development, and manufacture of real-time PCR kits, nucleic acid extraction kits, and automated nucleic acid extraction instruments in Turkey. It offers microbiology, genetic disorder, panel, sequencing, and food testing kits; and manual spin column and magnetic bead nucleic acid extraction kits, and automated NA extraction instrument kits. The company provides products for diseases, such as brucellosis, chlamydia trachomatis, cytomegalovirus, crimean-congo hemorrhagic fever, novel coronavirus (2019-NCoV)/SARS-CoV-2, epstein-barr virus, hepatitis B, hepatitis C, hepatitis D, herpes simplex virus, human immunodeficiency virus, human papillomavirus, JC and BK polyomaviruses, malaria, measles, meningitis, respiratory infection, parvovirus B19, torque teno virus, toxoplasmosis, tuberculosis, ureaplasma, and west nile virus diseases, as well as factor II, factor V leiden, and methylene-tetra-hydro-folate-reductase mutation diseases. Anatolia Tani ve Biyoteknoloji Ürünleri Ar-Ge Sanayi Ticaret A.S. is headquartered in Istanbul, Turkey.
www.anatoliageneworks.comRecent News: ANGEN.IS
View MorePerformance Overview: ANGEN.IS
Trailing total returns as of 4/30/2025, which may include dividends or other distributions. Benchmark is BIST 100 (XU100.IS) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ANGEN.IS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ANGEN.IS
View MoreValuation Measures
Market Cap
2.41B
Enterprise Value
2.20B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
4.54
Price/Book (mrq)
1.55
Enterprise Value/Revenue
4.16
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-41.31%
Return on Assets (ttm)
0.58%
Return on Equity (ttm)
-13.25%
Revenue (ttm)
529.83M
Net Income Avi to Common (ttm)
-218.88M
Diluted EPS (ttm)
-0.99
Balance Sheet and Cash Flow
Total Cash (mrq)
221.31M
Total Debt/Equity (mrq)
1.24%
Levered Free Cash Flow (ttm)
-101.16M